Search results
Michael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks By Investing.com
Investing.com· 5 days agoMichael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 7 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena via Yahoo Finance· 6 days agoMerck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial...
Gossamer sells rights to drug it hopes can rival a new Merck therapy
BioPharma Dive via Yahoo Finance· 2 days agoOne analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing...
Dow Jones Futures Rise: AI Stock Palantir Plunges On Earnings; Apple 'Let Loose' Event Next
Investor's Business Daily· 23 hours agoChipotle Mexican Grill, NXP Semiconductor, Texas Roadhouse and Tradeweb Markets — plus Dow Jones...
Cramer explains how to maintain a balanced portfolio as the economy slows
CNBC· 12 hours agoCNBC's Jim Cramer on Tuesday said Wall Street is currently going through a tricky stage of the...
Dow Jones Rises As Disney Dives On Sales Miss; Palantir Plunges On Earnings
Investor's Business Daily· 21 hours agoChipotle Mexican Grill, NXP Semiconductor, Texas Roadhouse and Tradeweb Markets — plus Dow Jones...
OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ...
GuruFocus.com via Yahoo Finance· 3 hours agoOPKO Health Inc (NASDAQ:OPK) has several promising pharmaceutical programs set to enter clinical trials, including a multi-specific oncology antibody and a vaccine licensed to Merck ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 2 days agoPRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region ...
A Look at Pharma ETFs Post Q1 Earnings
Zacks via Yahoo Finance· 19 hours agoThe U.S. drug giant reaffirmed its revenue guidance of $58.5-$61.5 billion and raised its adjusted earnings per share to $2.15-$2.35 from $2.05-$2.25 for...
